Safety Profile of First-Line Targeted Therapies in Elderly and/or Comorbid Chronic Lymphocytic Leukaemia Patients (Unfit Subpopulation). A Systematic Review and …
A Stożek-Tutro, M Reczek, P Kawalec - Critical Reviews in Oncology …, 2024 - Elsevier
This systematic literature review (CRD42023393903) and a Bayesian network meta-
analysis (NMA) aimed to assess the relative safety profile of first-line targeted therapies …
analysis (NMA) aimed to assess the relative safety profile of first-line targeted therapies …
Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review
A Visentin, S Frazzetto, L Trentin, A Chiarenza - Cancers, 2024 - mdpi.com
Simple Summary Chronic Lymphocytic Leukemia (CLL) is one of the most frequent leukemia
in the west countries for adult patients. It's typically a slow-growing disease and the majority …
in the west countries for adult patients. It's typically a slow-growing disease and the majority …
[HTML][HTML] Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents
A Galitzia, M Maccaferri, FR Mauro, R Murru… - Cancers, 2024 - mdpi.com
Simple Summary Targeted agents, such as Bruton's Tyrosine Kinase inhibitors and BCL-2
inhibitors, have transformed the treatment landscape for Chronic Lymphocytic Leukemia …
inhibitors, have transformed the treatment landscape for Chronic Lymphocytic Leukemia …
[PDF][PDF] Remissrunda–Nationellt vårdprogram för kronisk lymfatisk leukemi (KLL)
M Kättström - cancercentrum.se
Kronisk lymfatisk leukemi (KLL) är en hematologisk malignitet som har sitt ursprung i en
klonal expansion av mogna B-lymfocyter. Varje år diagnostiseras cirka 550–600 personer i …
klonal expansion av mogna B-lymfocyter. Varje år diagnostiseras cirka 550–600 personer i …